Clinical trials: sponsored by Zhejiang Cancer Hospital
Breast Cancer Metastatic
Real World Study of Bone Metastases in Patients with Advanced Breast Cancer
By analyzing the clinical data of patients with advanced breast cancer with bone metastasis admitted to our center from January 1, 2021 to February 28, 2023, this study aims to understand the real-world clinical diagnosis and…
- Trial name
- NCT06873997
- Where
- China
- Volunteers
- 737 people
- Sponsor
- Zhejiang Cancer Hospital
Radiation Pneumonitis
The Formulation of Compound Phellinus Igniarius Decoction on Radiation Pneumonitis
The objectives of this clinical trial were to determine the radioprotective effects and underlying biological mechanisms of Phellinus igniarius and its active components during radiotherapy in patients with thoracic malignant…
- Trial name
- NCT06861179
- Testing
- The formulation of Compound Phellinus igniarius decoction
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Leptomeningeal Metastases
Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases
With the rapid development of targeted drugs, the treatment of patients with leptomeningeal metastasis has become a very difficult problem in clinical work.
- Trial name
- NCT06861218
- Testing
- pemetrexed, vometinib
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Zhejiang Cancer Hospital
Diffuse Large B-cell Lymphoma (DLBCL)
Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
This study aims to observe and explore the efficacy and safety of pomalidomide combination with rituximab and Anti-PD-1 Antibody in Third or Later Line Therapy of diffuse large B-cell lymphoma (DLBCL)
- Trial name
- NCT06832228
- Testing
- Pomalidomide Combination With Rituximab and Anti-PD-1 Antibody （PPR）
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Primary Central Nervous System Lymphoma
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
This study aims to observe and explore the efficacy and safety of Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) regimen as first-line therapy for primary central nervous system diffuse large B-cell lymphomas(PCNS DLBCL)
- Trial name
- NCT06832267
- Testing
- Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhejiang Cancer Hospital
Intrahepatic Cholangiocarcinoma
GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence
Intrahepatic cholangiocarcinoma (ICC) arises from the epithelial cells of bile ducts and occurs proximal to the segmental biliary ducts.
- Trial name
- GOT (NCT05557578)
- Testing
- Tislelizumab combined with GEMOX (GOT) regimen
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma, Lenvatinib
Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
This is a monocenter, single-arm, open-label study to evaluate the efficacy and safety of Lenvatinib combined with Tislelizumab and TACE applied as neoadjuvant regimen for the patients of CNLC stage IB and IIA hepatocellular…
- Conditions
- Hepatocellular Carcinoma, Lenvatinib, Tislelizumab, TACE
- Trial name
- NCT05920863
- Testing
- TACE, Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital
Gastrointestinal Tumors
Combined Screening for Gastrointestinal Tumors
All participants are required to complete a questionnaire, a Helicobacter pylori (H. pylori) test, and a fecal immunochemical test (FIT).
- Trial name
- NCT06478030
- Testing
- questionnaire, Helicobacter pylori (H. pylori) test, fecal immunochemical test (FIT)
- Where
- 2 sites in China
- Volunteers
- 200,000 people
- Sponsor
- Zhejiang Cancer Hospital
Locally Advanced Nasopharyngeal Carcinoma
Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC
Nearly half of the world's nasopharyngeal cancer occurs in China, among which the highest incidence in Guangdong and Guangxi, so the nickname "Guangdong tumor".
- Trial name
- NCT06752382
- Testing
- Experimental drug
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Zhejiang Cancer Hospital
Ovarian Neoplasm Epithelial
Pharmacokinetic Study of Tranexamic Acid
Tranexamic acid is an effective anti fibrinolytic drug. Clinical studies have found that intravenous injection of tranexamic acid is more effective in reducing blood loss and transfusion in patients with advanced ovarian cancer…
- Trial name
- NCT06728670
- Testing
- Tranexamic acid Intravenous Infusion, TXA intramuscular injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
NSCLC
A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor
The combination of immunocheckpoint inhibitors and anti-angiogenesis therapy has synergistic anti-tumor effect and is a reasonable method to improve the prognosis of patients.
- Trial name
- NCT04691388
- Testing
- sintilimab combined with anlotinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Zhejiang Cancer Hospital
Tumor, Stroke
Different Intraoperative Blood Pressure Management on Postoperative Cognitive Function in Tumor Patients（PRECISION）
This is a randomized controlled study to explore whether perioperative blood pressure management with different strategies can reduce the incidence of delirium and postoperative cognitive impairment and serious perfusion related…
- Trial name
- PRECISION (NCT06711432)
- Testing
- Norepinephrine or phenylephrine
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Zhejiang Cancer Hospital
Triple-negative Breast Cancer, Bone Metastases
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
The goal of this clinical trial is to learn if Tislelizumab Combined with Nab-Paclitaxel works to treat patients of TNBC with bone metastasis as first line treatment. It will also learn about the safety of the combination.
- Trial name
- NCT06538896
- Testing
- Tislelizumab + Nab-Paclitaxel, Rankl inhibitor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Vulvar and Vaginal Cancer
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
To evaluate the efficacy and safety of cardunolizumab in combination with/without chemotherapy ± bevacizumab for recurrent or metastatic vulvar and vaginal cancers that are not amenable to radical treatment.
- Trial name
- NCT06292689
- Testing
- Cardunolizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Carcinoma, Neoadjuvant Chemoradiotherapy
Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma
Esophageal cancer is one of the most common cancers worldwide, while more than half new cases and deaths occurred in China. Surgery is the main curative treatment for this disease, the 5-year survival of EC remains poor, since…
- Conditions
- Esophageal Carcinoma, Neoadjuvant Chemoradiotherapy, Surgery
- Trial name
- Neo-DRATEC (NCT03381651)
- Testing
- Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation, Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation
- Where
- 2 sites in China
- Volunteers
- 147 people
- Sponsor
- Zhejiang Cancer Hospital
Double-expressor Lymphoma
RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
This is a prospective, single-arm, multicenter clinical study to evaluate the efficacy and safety of chidamide, rituximab combined with lenalidomide sequential immunochemotherapy in the treatment of newly diagnosed elderly…
- Trial name
- NCT06674096
- Testing
- RLC-CRCHOP
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
This trial is An open-label, multicohort, multicenter clinical study aimed at evaluating the efficacy and safety of the cadonilimab combination regimen in the treatment of advanced HER-2 positive gastric/gastroesophageal junction…
- Trial name
- NCT06650332
- Testing
- cadonilimab, Trastuzumab, XELOX
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Zhejiang Cancer Hospital
Biliary Tract Carcinoma
SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma
This is a single-arm, open, single-center Phase II clinical study to observe and evaluate the efficacy and safety of SBRT sequential surufatinib combined with immunotherapy in patients with locally unresectable or recurrent…
- Trial name
- NCT06199882
- Testing
- SBRT Sequential Surufatinib Combined With Immunotherapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharynx Cancer
GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
This research aims to assess both effectiveness and safety of combining R-GEP regimen comprising gemcitabine, recombinant human endostatin, and cerexinib with low- and high-dose radiotherapy in managing unresectable recurrent…
- Trial name
- NCT06611826
- Testing
- GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy
- Volunteers
- 41 people
- Sponsor
- Zhejiang Cancer Hospital
Colon Cancer, Colon Cancer (Stage II &Amp;Amp;Amp; III)
ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study
The goal of this clinical trial is to explore the disease-free survival period of elderly patients with high-risk stage II and stage III colon cancer based on ctDNA detection.
- Trial name
- ZJCH-CRCC-1 (NCT06609551)
- Testing
- 6-month adjuvant chemotherapy with 5-FU monotherapy, XELOX intensive treatment group
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Zhejiang Cancer Hospital